
    
      Primary Objective:

        1. To provide additional clinical and safety data on long term following administration of
           Copper Histidinate treatment in patients treated with Copper Histidinate under Protocols
           09-CH-0059 and 90-CH0149 and untreated patients previously identified and/or enrolled in
           Protocol 09-CH-0059.

        2. To provide additional Historical Control data on Menkes disease patients.
    
  